REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
Terminated · Phase 2 · NCT06237309
Conditions: Heart Failure
At a glance
- Research payments reported, 2025
- $114,863
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 89
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN5381 (drug), Placebo (drug)
- Dates
- Started 2024-04-11; completion 2025-12-29
- Results posted
- Not yet
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should). The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
From ClinicalTrials.gov, last updated 2026-01-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $114,863 in research payments for this study in 2025 (48 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alfonso Gonzalez-rodriguez, MD Internal Medicine · Orlando, FL
- Mark J. Rosenthal, D.O. Family Medicine · Homestead, FL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Site PArtners Inc $52,135
- $38,165
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center $24,563
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.